PANTERA is focused on the large-scale production of actinium-225 (Ac-225), a promising alpha-emitting radioisotope that plays a crucial role in targeted radio therapy (TRT) for cancer treatment. The company aims to enhance the accessibility of innovative cancer therapies by leveraging Ac-225, which is integral to the development of personalized treatments for tumors. By prioritizing the production of this radioisotope, PANTERA seeks to provide new hope for cancer patients through advanced radiopharmaceuticals and theranostics.

In addition to its commitment to Ac-225 production, PANTERA operates as a joint venture between IBA and SCK CEN, indicating a collaborative approach to advancing cancer treatment technologies. The company emphasizes the importance of securing a reliable supply chain for Ac-225, which is essential for the effective implementation of targeted therapies. Through its initiatives, PANTERA is positioned to contribute significantly to the field of cancer treatment, focusing on innovative solutions that improve patient outcomes.

Belgium

PanTera aims to secure the large-scale production of actinium-225 (225Ac), one of the most promising alpha-emitting radioisotopes to fight cancers by Targeted RadioTherapy (TRT). By working towards this large-scale production, PanTera's ultimate goal is to improve the accessibility of future innovative cancer therapy based on 225Ac and theranostics in general.

PANTERA

Company Details